Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
Identifieur interne : 003084 ( PubMed/Curation ); précédent : 003083; suivant : 003085Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
Auteurs : Christopher G. Goetz [États-Unis] ; Werner Poewe ; Olivier Rascol ; Cristina SampaioSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2005.
English descriptors
- KwdEn :
- Amantadine (therapeutic use), Antiparkinson Agents (therapeutic use), Apomorphine (therapeutic use), Benzophenones (therapeutic use), Benzothiazoles, Bromocriptine (therapeutic use), Catechol O-Methyltransferase Inhibitors, Deep Brain Stimulation (methods), Dihydroergocryptine (therapeutic use), Ergolines (therapeutic use), Fetal Tissue Transplantation (methods), Globus Pallidus (surgery), Humans, Indans (therapeutic use), Indoles (therapeutic use), Levodopa (therapeutic use), Lisuride (therapeutic use), Mesencephalon (cytology), Mesencephalon (embryology), Monoamine Oxidase Inhibitors (therapeutic use), Neurosurgical Procedures (methods), Nitrophenols (therapeutic use), Parkinson Disease (drug therapy), Parkinson Disease (surgery), Pergolide (therapeutic use), Piribedil (therapeutic use), Selegiline (therapeutic use), Thiazoles (therapeutic use).
- MESH :
- chemical , therapeutic use : Amantadine, Antiparkinson Agents, Apomorphine, Benzophenones, Bromocriptine, Dihydroergocryptine, Ergolines, Indans, Indoles, Levodopa, Lisuride, Monoamine Oxidase Inhibitors, Nitrophenols, Pergolide, Piribedil, Selegiline, Thiazoles.
- chemical : Benzothiazoles, Catechol O-Methyltransferase Inhibitors.
- cytology : Mesencephalon.
- drug therapy : Parkinson Disease.
- embryology : Mesencephalon.
- methods : Deep Brain Stimulation, Fetal Tissue Transplantation, Neurosurgical Procedures.
- surgery : Globus Pallidus, Parkinson Disease.
- Humans.
Abstract
The objective of this study is to update a previous evidence-based medicine (EBM) review on Parkinson's disease (PD) treatments, adding January 2001 to January 2004 information. The Movement Disorder Society (MDS) Task Force prepared an EBM review of PD treatments covering data up to January 2001. The authors reviewed Level I (randomized clinical trials) reports of pharmacological and surgical interventions for PD, published as full articles in English (January 2001-January 2004). Inclusion criteria and ranking followed the original program and adhered to EBM methodology. For Efficacy Conclusions, treatments were designated Efficacious, Likely Efficacious, Non-Efficacious, or Insufficient Data. Four clinical indications were considered for each intervention: prevention of disease progression; treatment of Parkinsonism, as monotherapy and as adjuncts to levodopa where indicated; prevention of motor complications; treatment of motor complications. Twenty-seven new studies qualified for efficacy review, and others covered new safety issues. Apomorphine, piribedil, unilateral pallidotomy, and subthalamic nucleus stimulation moved upward in efficacy ratings. Rasagiline, was newly rated as Efficacious monotherapy for control of Parkinsonism. New Level I data moved human fetal nigral transplants, as performed to date, from Insufficient Data to Non- efficacious for the treatment of Parkinsonism, motor fluctuations, and dyskinesias. Selegiline was reassigned as Non-efficacious for the prevention of dyskinesias. Other designations did not change. In a field as active in clinical trials as PD, frequent updating of therapy-based reviews is essential. We consider a 3-year period a reasonable time frame for published updates and are working to establish a Web-based mechanism to update the report in an ongoing manner.
DOI: 10.1002/mds.20464
PubMed: 15818599
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003084
Links to Exploration step
pubmed:15818599Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.</title>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G" last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurological Sciences, Department of Pharmacology, Rush University Medical Center, Chicago, Illinois 60612, USA. cgoetz@rush.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurological Sciences, Department of Pharmacology, Rush University Medical Center, Chicago, Illinois 60612</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
</author>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2005">2005</date>
<idno type="doi">10.1002/mds.20464</idno>
<idno type="RBID">pubmed:15818599</idno>
<idno type="pmid">15818599</idno>
<idno type="wicri:Area/PubMed/Corpus">003084</idno>
<idno type="wicri:Area/PubMed/Curation">003084</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.</title>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G" last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurological Sciences, Department of Pharmacology, Rush University Medical Center, Chicago, Illinois 60612, USA. cgoetz@rush.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurological Sciences, Department of Pharmacology, Rush University Medical Center, Chicago, Illinois 60612</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
</author>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2005" type="published">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amantadine (therapeutic use)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Apomorphine (therapeutic use)</term>
<term>Benzophenones (therapeutic use)</term>
<term>Benzothiazoles</term>
<term>Bromocriptine (therapeutic use)</term>
<term>Catechol O-Methyltransferase Inhibitors</term>
<term>Deep Brain Stimulation (methods)</term>
<term>Dihydroergocryptine (therapeutic use)</term>
<term>Ergolines (therapeutic use)</term>
<term>Fetal Tissue Transplantation (methods)</term>
<term>Globus Pallidus (surgery)</term>
<term>Humans</term>
<term>Indans (therapeutic use)</term>
<term>Indoles (therapeutic use)</term>
<term>Levodopa (therapeutic use)</term>
<term>Lisuride (therapeutic use)</term>
<term>Mesencephalon (cytology)</term>
<term>Mesencephalon (embryology)</term>
<term>Monoamine Oxidase Inhibitors (therapeutic use)</term>
<term>Neurosurgical Procedures (methods)</term>
<term>Nitrophenols (therapeutic use)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (surgery)</term>
<term>Pergolide (therapeutic use)</term>
<term>Piribedil (therapeutic use)</term>
<term>Selegiline (therapeutic use)</term>
<term>Thiazoles (therapeutic use)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Amantadine</term>
<term>Antiparkinson Agents</term>
<term>Apomorphine</term>
<term>Benzophenones</term>
<term>Bromocriptine</term>
<term>Dihydroergocryptine</term>
<term>Ergolines</term>
<term>Indans</term>
<term>Indoles</term>
<term>Levodopa</term>
<term>Lisuride</term>
<term>Monoamine Oxidase Inhibitors</term>
<term>Nitrophenols</term>
<term>Pergolide</term>
<term>Piribedil</term>
<term>Selegiline</term>
<term>Thiazoles</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Benzothiazoles</term>
<term>Catechol O-Methyltransferase Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Mesencephalon</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="embryology" xml:lang="en"><term>Mesencephalon</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Deep Brain Stimulation</term>
<term>Fetal Tissue Transplantation</term>
<term>Neurosurgical Procedures</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Globus Pallidus</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The objective of this study is to update a previous evidence-based medicine (EBM) review on Parkinson's disease (PD) treatments, adding January 2001 to January 2004 information. The Movement Disorder Society (MDS) Task Force prepared an EBM review of PD treatments covering data up to January 2001. The authors reviewed Level I (randomized clinical trials) reports of pharmacological and surgical interventions for PD, published as full articles in English (January 2001-January 2004). Inclusion criteria and ranking followed the original program and adhered to EBM methodology. For Efficacy Conclusions, treatments were designated Efficacious, Likely Efficacious, Non-Efficacious, or Insufficient Data. Four clinical indications were considered for each intervention: prevention of disease progression; treatment of Parkinsonism, as monotherapy and as adjuncts to levodopa where indicated; prevention of motor complications; treatment of motor complications. Twenty-seven new studies qualified for efficacy review, and others covered new safety issues. Apomorphine, piribedil, unilateral pallidotomy, and subthalamic nucleus stimulation moved upward in efficacy ratings. Rasagiline, was newly rated as Efficacious monotherapy for control of Parkinsonism. New Level I data moved human fetal nigral transplants, as performed to date, from Insufficient Data to Non- efficacious for the treatment of Parkinsonism, motor fluctuations, and dyskinesias. Selegiline was reassigned as Non-efficacious for the prevention of dyskinesias. Other designations did not change. In a field as active in clinical trials as PD, frequent updating of therapy-based reviews is essential. We consider a 3-year period a reasonable time frame for published updates and are working to establish a Web-based mechanism to update the report in an ongoing manner.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">15818599</PMID>
<DateCreated><Year>2005</Year>
<Month>05</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted><Year>2005</Year>
<Month>09</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised><Year>2014</Year>
<Month>11</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>20</Volume>
<Issue>5</Issue>
<PubDate><Year>2005</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.</ArticleTitle>
<Pagination><MedlinePgn>523-39</MedlinePgn>
</Pagination>
<Abstract><AbstractText>The objective of this study is to update a previous evidence-based medicine (EBM) review on Parkinson's disease (PD) treatments, adding January 2001 to January 2004 information. The Movement Disorder Society (MDS) Task Force prepared an EBM review of PD treatments covering data up to January 2001. The authors reviewed Level I (randomized clinical trials) reports of pharmacological and surgical interventions for PD, published as full articles in English (January 2001-January 2004). Inclusion criteria and ranking followed the original program and adhered to EBM methodology. For Efficacy Conclusions, treatments were designated Efficacious, Likely Efficacious, Non-Efficacious, or Insufficient Data. Four clinical indications were considered for each intervention: prevention of disease progression; treatment of Parkinsonism, as monotherapy and as adjuncts to levodopa where indicated; prevention of motor complications; treatment of motor complications. Twenty-seven new studies qualified for efficacy review, and others covered new safety issues. Apomorphine, piribedil, unilateral pallidotomy, and subthalamic nucleus stimulation moved upward in efficacy ratings. Rasagiline, was newly rated as Efficacious monotherapy for control of Parkinsonism. New Level I data moved human fetal nigral transplants, as performed to date, from Insufficient Data to Non- efficacious for the treatment of Parkinsonism, motor fluctuations, and dyskinesias. Selegiline was reassigned as Non-efficacious for the prevention of dyskinesias. Other designations did not change. In a field as active in clinical trials as PD, frequent updating of therapy-based reviews is essential. We consider a 3-year period a reasonable time frame for published updates and are working to establish a Web-based mechanism to update the report in an ongoing manner.</AbstractText>
<CopyrightInformation>Copyright 2005 Movement Disorder Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goetz</LastName>
<ForeName>Christopher G</ForeName>
<Initials>CG</Initials>
<AffiliationInfo><Affiliation>Department of Neurological Sciences, Department of Pharmacology, Rush University Medical Center, Chicago, Illinois 60612, USA. cgoetz@rush.edu</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Poewe</LastName>
<ForeName>Werner</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y"><LastName>Rascol</LastName>
<ForeName>Olivier</ForeName>
<Initials>O</Initials>
</Author>
<Author ValidYN="Y"><LastName>Sampaio</LastName>
<ForeName>Cristina</ForeName>
<Initials>C</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001577">Benzophenones</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D052160">Benzothiazoles</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D065098">Catechol O-Methyltransferase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004873">Ergolines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007189">Indans</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007211">Indoles</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008996">Monoamine Oxidase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009596">Nitrophenols</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>003N66TS6T</RegistryNumber>
<NameOfSubstance UI="C031967">rasagiline</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>030PYR8953</RegistryNumber>
<NameOfSubstance UI="C046649">ropinirole</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>14611-51-9</RegistryNumber>
<NameOfSubstance UI="D012642">Selegiline</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>24MJ822NZ9</RegistryNumber>
<NameOfSubstance UI="D010479">Pergolide</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>25447-66-9</RegistryNumber>
<NameOfSubstance UI="D025443">Dihydroergocryptine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>3A64E3G5ZO</RegistryNumber>
<NameOfSubstance UI="D001971">Bromocriptine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>46627O600J</RegistryNumber>
<NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>83619PEU5T</RegistryNumber>
<NameOfSubstance UI="C061333">pramipexole</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>BF4C9Z1J53</RegistryNumber>
<NameOfSubstance UI="D000547">Amantadine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>CIF6334OLY</RegistryNumber>
<NameOfSubstance UI="C066340">tolcapone</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>DO22K1PRDJ</RegistryNumber>
<NameOfSubstance UI="D010891">Piribedil</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>E0QN3D755O</RegistryNumber>
<NameOfSubstance UI="D008090">Lisuride</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>LL60K9J05T</RegistryNumber>
<NameOfSubstance UI="C047047">cabergoline</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>N21FAR7B4S</RegistryNumber>
<NameOfSubstance UI="D001058">Apomorphine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000547">Amantadine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D001058">Apomorphine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D001577">Benzophenones</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D052160">Benzothiazoles</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D001971">Bromocriptine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D065098">Catechol O-Methyltransferase Inhibitors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D046690">Deep Brain Stimulation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D025443">Dihydroergocryptine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004873">Ergolines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D016332">Fetal Tissue Transplantation</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005917">Globus Pallidus</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000601">surgery</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D007189">Indans</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D007211">Indoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008090">Lisuride</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008636">Mesencephalon</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000196">embryology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008996">Monoamine Oxidase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D019635">Neurosurgical Procedures</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D009596">Nitrophenols</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000601">surgery</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010479">Pergolide</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010891">Piribedil</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D012642">Selegiline</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D013844">Thiazoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>47</NumberOfReferences>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year>
<Month>4</Month>
<Day>9</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2005</Year>
<Month>9</Month>
<Day>2</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2005</Year>
<Month>4</Month>
<Day>9</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="doi">10.1002/mds.20464</ArticleId>
<ArticleId IdType="pubmed">15818599</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003084 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 003084 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:15818599 |texte= Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:15818599" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
![]() | This area was generated with Dilib version V0.6.23. | ![]() |